Cognito Therapeutics has partnered with the Initiative to Change the D-Word and is committed to eliminating the use of the word “dementia” across all internal and external communications.
The move is presented as an effort to advance more precise, patient-centered language that reduces stigma and supports earlier recognition of cognitive change. The company is updating terminology across scientific materials, patient resources, clinical study communications and public-facing content.
The Initiative to Change the D-Word is a 501(c)(3) nonprofit that seeks to eliminate use of the terms dementia and demented to reduce stigma and encourage earlier detection and treatment.
Cognito is a late clinical-stage neurotechnology firm developing Spectris, an investigational at-home neuroprotective therapy platform that uses non-invasive, sensory-driven neurostimulation to evoke gamma frequency brain activity.
The company says feasibility studies have shown potential for Spectris to preserve cognition and daily function and to slow brain atrophy in people diagnosed with mild-to-moderate Alzheimer’s disease.
